Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real‐world effectiveness and economic assessment
Pediatric Pulmonology · 2023
DOI: 10.1002/ppul.26647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2023. Verfasst von Yuncui Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, National Clinical Research Center for Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, Nation…. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Respiratory Research Project of the National Clinical Research Center for Respiratory Diseases, Asthma medication evaluation project in children commissioned by the Beijing Medical and Health Economic Research Association.
Abstract (Originalsprache)
Introduction
The study aims to compare the real‐world effectiveness and economy of the budesonide/formoterol reliever and maintenance therapy (SMART) with fixed‐dose inhaled corticosteroids (ICS)/long‐acting b‐agonist (LABA) or ICS alone plus as‐needed, short‐acting β2 agonists (SABA) in pediatric patients.
Methods
The outpatient data warehouse of a hospital in China was used. A total of 103 patients under 18 years old in the SMART group and 63 patients in the control group were included from January 1, 2020 to December 31, 2021. The effectiveness was assessed using asthma attacks and lung function at baseline, 6 months and 12 months follow‐up. Cost‐effectiveness analysis was performed with a three‐state Markov model from the healthcare system perspective. One‐way sensitivity analyses and probabilistic sensitivity analyses were performed to check the robustness of the results.
Results
The SMART regimen was more effective than other strategies in reducing the risk of mild and severe attacks in the real‐life management of childhood asthma. Patients in both groups showed significant improvement in lung function at 6 and 12 months in contrast to baseline. Compared with other strategies, the forced expiratory volume in 1 s (FEV 1 ) level in the SMART group was markedly improved at 6 months. The total cost of outpatient service using the SMART regimen was lower than that of other strategies, while the drug costs were similar in different groups. Incremental cost‐effectiveness analysis results showed that using the SMART regimen reduced the total cost by approximately CNY 10,516.11 per year with a 0.12 quality‐adjusted life year (QALYs) increase. Sensitive analyses supported that the SMART regimen was the dominant choice at the willingness‐to‐pay threshold of CNY 85,698, per capita GDP in China.
Conclusions
Collectively, our findings indicate that the real‐world effectiveness and economy of the SMART regimen are superior to the traditional strategies in pediatric asthma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Center, National Clinical Research Center for Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- National Health Development Research Center, National Health Commission, Beijing, China.
- Department of Allergy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
ORCID-Profile: Yuncui Yu
Förderung
- Respiratory Research Project of the National Clinical Research Center for Respiratory Diseases
- Asthma medication evaluation project in children commissioned by the Beijing Medical and Health Economic Research Association
Zitieren
APA
Yu, Y., Cao, W., Xiao, Y., Li, A., Huang, H., Liu, K., Hu, L., Hou, X., Xiang, L., & Wang, X. (2023). Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real‐world effectiveness and economic assessment. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26647
Vancouver
Yu Y, Cao W, Xiao Y, Li A, Huang H, Liu K, et al. Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real‐world effectiveness and economic assessment. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26647
BibTeX
@article{Yu2023,
author = {Yu, Yuncui and Cao, Wang and Xiao, Yue and Li, Ang and Huang, Huijie and Liu, Kejun and Hu, Lihua and Hou, Xiaoling and Xiang, Li and Wang, Xiaoling},
title = {Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real‐world effectiveness and economic assessment},
journal = {Pediatric Pulmonology},
year = {2023},
doi = {10.1002/ppul.26647}
}
EUVIMED